Condition
Cutaneous Melanoma, Stage IV
Total Trials
5
Recruiting
1
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
2Total
Early P 1 (1)
P 2 (1)
Trial Status
Completed2
Unknown1
Recruiting1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07148245Recruiting
Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma
NCT03719131Phase 2Active Not Recruiting
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
NCT04853602Unknown
IFx-Hu2.0 Expanded Access Program
NCT03655756Early Phase 1Completed
pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma
NCT03663647CompletedPrimary
Advanced Melanoma in Russian Experience
Showing all 5 trials